---
title: "AKRO.US (AKRO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AKRO.US/news.md"
symbol: "AKRO.US"
name: "AKRO.US"
parent: "https://longbridge.com/en/quote/AKRO.US.md"
datetime: "2026-05-21T10:32:27.137Z"
locales:
  - [en](https://longbridge.com/en/quote/AKRO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AKRO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AKRO.US/news.md)
---

# AKRO.US (AKRO.US) — Related News

### [22:54 ETCadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026](https://longbridge.com/en/news/283430060.md)
*2026-04-21T02:57:29.000Z*
> Akeso, Inc. announced positive Phase II results from the COMPASSION-26 study of cadonilimab, a bispecific antibody, in c

### [16:13 ETAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/282739590.md)
*2026-04-14T20:14:02.000Z*
> Halper Sadeh LLC is investigating Kezar Life Sciences, Equitable Holdings, and Urgent.ly for potential violations of fed

### [23:28 ETAkeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L) 1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026](https://longbridge.com/en/news/281824072.md)
*2026-04-07T03:32:26.000Z*
> Akeso, Inc. presented updated data on cadonilimab combination therapy for advanced NSCLC at ELCC 2026. The Phase Ib/II s

### [05:40 ETIvonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026](https://longbridge.com/en/news/281162118.md)
*2026-03-31T09:42:16.000Z*
> Akeso, Inc. presented health-related quality of life (HRQoL) data from the HARMONi-2 study at the 2026 European Lung Can

### [22:05 ETAkeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance](https://longbridge.com/en/news/279189292.md)
*2026-03-16T02:07:17.000Z*
> Akeso, Inc. announced that its trispecific antibody, AK150, has received IND clearance for clinical trials targeting adv

### [Aker BioMarine Registers Share Capital Increase from Employee Share Program](https://longbridge.com/en/news/278917834.md)
*2026-03-12T16:34:25.000Z*
> Aker BioMarine Registers Share Capital Increase from Employee Share Program

### [21:59 ETACROBiosystems fördert Innovationen bei JPM Spotlight-Sessions von bioSeedin und unterstützt strategisch den Aufbau globaler Partnerschaften](https://longbridge.com/en/news/275692064.md)
*2026-02-12T03:00:36.000Z*
> ACROBiosystems participated in the BIOSeedin Winter Innovation Partnering Summit on January 11, ahead of J.P. Morgan 202

### [Agomab Announces Launch of Initial Public Offering](https://longbridge.com/en/news/274511766.md)
*2026-02-02T12:00:00.000Z*
> AgomAb Therapeutics NV has announced the launch of its initial public offering (IPO) of 12,500,000 American Depositary S